Copyright
©The Author(s) 2015.
World J Clin Oncol. Aug 10, 2015; 6(4): 35-42
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.35
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.35
Institution/group | n | Radiation technique | Comp Rx | GI toxicity | GU toxicity | Other toxicity |
Continuous infusion 5-fluorouracil | ||||||
SWOG[29] | 30 | Whole pelvis if not surgically negative to 45 Gy + 70.2 Gy 3DCRT to prostate | 97% | Gr 3: 7% Gr 4: 3% | Gr 3: 3% Gr 4: 3% | Multiple Gr 3: 13% (cumulative) |
Daily estramustine phosphate + weekly vincristine | ||||||
Henry Ford Hospital[36] | 65 | 4-field pelvis to 45 Gy + 65-70 Gy 3DCRT to prostate | 71% | Gr 3: 0% Gr 4: 2% | Gr 3: 0% Gr 4: 0% | Leukopenia Gr 3: 2% |
MSKCC[37] | 27 | 3DCRT to prostate and SV | 85% | Gr 3: 35% Gr 4: 0% | Gr 3: 48% Gr 4: 11% | Hematologic Gr 3: 8% Liver Gr 3: 7% |
Daily estramustine phosphate | ||||||
Wayne State[39] | 18 | Prostate and SV to 50.4-70.2 Gy via 4-field + 3DCRT to prostate 70.2 Gy | 78% | Not reported | Not reported | Leukopenia Gr 3: 12% Venous thrombosis Gr: 6% MI Gr 4: 6% |
Weekly docetaxel | ||||||
UMDNJ[52] | 22 | 3DCRT to prostate to 70.2 Gy | 100% | Gr 3: 9% Gr 4: 0% | Gr 3: 0% Gr 4: 0% | No Gr 3 or 4 |
Europe[53] | 50 | 4-field pelvis to 46 Gy + 70 Gy to prostate and proximal SV via 3DCRT or IMRT | 92% | Gr 3: 6% Gr 4: 2% | Gr 3: 4% Gr 4: 0% | MI Gr 4: 2% |
St. Peter’s[70] | 20 | 72 Gy delivered via IMRT (no further details) | 85% | Gr 3: 0% Gr 4: 0% | Gr 3: 0% Gr 4: 0% | Dypsnea Gr 3: 5% Dehydration Gr 3: 10% |
UNC[72] | 18 | Prostate and proximal SV 78 Gy with IMRT | 89% | Gr 3: 11% Gr 4: 0% | Gr 3: 0% Gr 4: 0% | Leukopenia Gr 3: 28% Liver Gr 3: 6% |
Medical University of South Carolina[73] | 19 | Prostate and proximal SV 45 Gy + 77.4 Gy prostate with IMRT | 89% | Gr 3: 11% Gr 4: 0% | Gr 3: 0% Gr 4: 0% | Fatigue Gr 3: 11% |
Biweekly Paclitaxel | ||||||
NYU[64] | 22 | 4-field pelvis to 39.6 Gy + 63-73.8 Gy to prostate and proximal SV via 3DCRT | 100% | Gr 3: 18% Gr 4: 0% | Gr 3: 0% Gr 4: 0% | No Gr 3 or 4 |
- Citation: Cooper BT, Sanfilippo NJ. Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol 2015; 6(4): 35-42
- URL: https://www.wjgnet.com/2218-4333/full/v6/i4/35.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i4.35